Korea Business News Agency - NSP NEWS AGENCY.

(Seoul=NSP NEWS AGENCY) = Immuneoncia, a company specializing in immunotherapy drugs, passed the technology evaluation for KOSDAQ technology special listing.

Immuneoncia was established as a 51:49 joint venture by Yuhan Corporation and Sorrento Therapeutics of the U.S. in 2016, and Yuhan Corporation holds a 67% stake after acquiring all of the partner's shares at the end of last year.

Immuneonsia has received technical evaluations from two professional evaluation agencies designated by the Korea Exchange(KRX) and is eligible to request preliminary screening for KOSDAQ listing. The listing manager is Korea Investment & Securities.

“Based on the results of this technology assessment, we will apply for listing on KOSDAQ this year, which will accelerate the development of our core pipelines that are currently in the clinical stage, as well as the non-clinical development of subsequent pipelines and the acquisition of new candidates,” said CEO of Immuneoncia.

Immuneoncia is a company developing immune checkpoint inhibitors targeting T cells and macrophages.

By Soon-ki Lee(s8789@nspna.com) and Bok-hyun Lee(bhlee2016@nspna.com)

ⓒNSP News Agency·NSP TV. All rights reserved. Prohibits using to train AI models.